Company
Theralase Technologies Inc
CVE:TLT
Theralase Technologies Inc is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers.
80 stories
Theralase Technologies leads the way in light-activated cancer therapies
Positive releases have centred around its photodynamic therapy technology
Theralase Technologies receives go-ahead to expand its photodynamic technology into Chinese market
The biotech firm has been granted a 'Notice of Acceptance' by the Chinese patent office for its photoDynamic compounds
Theralase Technologies further bolstered as TLD-1433 shown to be effective against cervical cancer
The light activated compound has now been proven to be effective against cervical cancer.
Theralase Technologies sees 14% increase in half year revenue as it ramps up sales teams
The group's therapeutic laser technology (TLT) division is commercializing the next-generation TLC-2000 therapeutic medical laser system
Theralase Technologies lifted by positive independent scientific study of its anti-cancer drug range
"The clinical utility of PDC [photo dynamic compounds] super-catalysts cannot be understated, having the potential to overcome variations in light dosimetry and other issues that have prohibited the application of PDT [photo dynamic therapy
Theralase Technologies' lead compound shown to destroy lung cancer
The latest data comes from pre-clinical research carried out by Dr Kazuhiro Yasufuku and his team in Toronto
Theralase Technologies moves to second phase in bladder cancer trial
As reported last week, the treatment of the first three patients in the study was a success.
Theralase Technologies shares rocket on TLD-1433 clinical trial findings
The candidate is a light activated photo dynamic compound (PDC)
Theralase's technology lauded in new scientific study
The study, on mice, concluded that low-intensity laser therapy was effective in treating arthritis.
TheraLase Technologies boosted by further patent for lead cancer compound
The biomedical firm received a second patent for its lead anti-cancer compound TLD-1433.
Theralase Technologies boosted as benefits of TLD-1433 outlined at conference
Theralase's president and chief executive said he was delighted about the audience at the conference.
Canada's Theralase qualifies for listing on OTCQX in US
Theralase has met all the requirements of the OTCQX exchange and its shares can now be traded more easily by US investors
Theralase in TLC-2000 rethink as sales fail to meet ambitious targets
Sales in the first quarter rose, but not as quickly as expected, prompting a decision to overhaul the flagship TLC-2000 tissue healing device
Theralase to expand bladder cancer trial after initial success
Theralase's Photo Dynamic Therapy technology is a "search and destroy" treatment for cancer cells
Theralase Technologies continues its journey to clinical-stage
Theralase's pipeline includes numerous highly effective drug candidates, in various advanced stages of preclinical development.
TheraLase Technologies treats third patient with lead cancer compound
The procedure sees Theralase's lead anti-cancer compound put through the urethra into the bladder
Archive
Proactive headlines, including Arizona Silver Exploration, Royal Road Minerals and more
A look at some of the Proactive US headine stories of the day
TheraLase Technologies treats second patient with its lead cancer compound
TheraLase Technologies said a second patient had been treated with its photo dynamic therapy (PDT)
TheraLase Technologies' latest research on anti-cancer compounds to be published
Theralase's photo dynamic compounds (PDCs) are able to localize to cancer cells
TheraLase Technologies welcomes first human testing of its lead cancer compound
TheraLase Technologies Inc revealed its photo dynamic therapy technology had been used for the first time in human clinical testing - a major milestone.
TheraLase Technologies shares up on positive data on lead cancer compound
TheraLase Technologies has received more good news on its lead cancer treating compound
Laser specialist TheraLase Technologies primed for a pivotal year
Unlike many fledgling med-tech companies it is generating revenues and thinks there is scope to significantly increase turnover in the next few years.
Theralase adopts advance notice bylaw
Theralase Technologies Inc said on Tuesday it has adopted bylaw No. 3 to establish a framework for the advance notice of nominations of directors by shareholders of Theralase
Theralase starts enrolling for bladder cancer study
Theralase's Photo Dynamic Therapy division develops specially designed molecules that localize to cancer cells and then when laser light activated, effectively destroy them
Theralase Technologies gets stability boost for cancer treatment
Theralase is aiming for a Phase Ib clinical trial for patients afflicted with Non-Muscle Invasive Bladder Cancer
Theralase completes C$4.27mln public offering
Theralase Technologies Inc closed a public offering of units, raising C$4.2mln, the company said on Thursday
Theralase Technologies Inc to raise funds
The funds will be used to finance R&D activities by Theralase's Photo Dynamic Therapy division, commercialization activities by Theralase's Therapeutic Laser Technology division
Theralase tempers full-year sales expectations
The recently-released TLC-2000 is a big improvement on its predecessor and was expected to sell well
Theralase's PDT can increase GMB cancer survival by 925%
Theralase Technologies on Friday said its photodynamic therapy technology has been found to have the ability to increase survival by 925% in a very aggressive form of brain cancer, known as glioblastoma multiforme
Theralase receives Health Canada nod for TLC trial
Theralase Technologies Inc. said on Thursday Health Canada has granted investigational testing authorisation approval to use its patent-pending TLC-3200 photodynamic therapy laser system and TLC-3400 dosimetry fibre optic cage technology
Promising results for Theralase's technology in cancer test
It was only a small test on one rat, but the results were astonishing
Theralase expects bladder cancer trial green light by end of November
Pending Health Canada approval of the ITA, Theralase will immediately commence enrolment of patients into a Phase Ib clinical study in the treatment of non-muscle invasive bladder cancer.
Theralase seeks green light to start bladder cancer study
Theralase has been hard at work for a long time preparing for this application
Theralase receives US patent for TLD-1433 drug
Theralase Technologies said on Monday it has been granted a US patent for its lead anti-cancer drug, TLD-1433, by the United States Patent and Trademark Office
Theralase's laser technology: "It's light, Jim, but not as we know it"
Theralase's "bread & butter" business is the clinically proven therapeutic laser technology, being used to treat skin, muscle and nerve damage, while the photo dynamics compounds technology in development promises new hope for cancer suffer
Theralase set for phase Ib study for bladder cancer
The study will be conducted by the Department of Urology at the University Health Network (UHN)
Theralase to nearly double revenues as gears up for BRIC demand says Zacks
Theralase Technologies revenues are expected to nearly double this year, as the company focuses on demand from BRIC economies, according to an upbeat assessment from Zacks Investment Research
Theralase boosted by Canada revenues jump
Theralase Technologies shares rise after the company reports a 40% jump in total revenues for its fiscal 2015 and a near-doubling in Canada
Theralase Technologies Inc extends research partnership with UHN
The University Health Network (UHN) is one of the top-five cancer research institutes in the world.
Theralase Technologies' anti-cancer compound passes milestone
Proving stability in clinical trials means the drug can be used to treat patients in a clinical study
Theralase Technologies cancer treatment study published in medical journal
Photochemical & Photobiological Sciences is a publication of the Royal Society of Chemistry that focuses on photodynamic therapy.
US Risers & Fallers: PharmaCyte, Theralase, J.P. Morgan, MagneGas, Gold Resource, Best Buy
Best Buy shares sink after the electronics company cuts outlook following disappointing holiday sales.
Theralase debuts next generation therapeutic laser in US
The Canadian biotech maker will be performing product demonstrations of the TLC-2000 at a Las Vegas seminar.
Theralase Technologies gets clinical trial go-ahead
Health Canada has no objection to the proposed Phase Ib clinical study.
Theralase approved to sell next-gen laser in United States
The new TLC-2000 system, for temporary pain relief from knee disorders, can now immediately be marketed in the US,